Emet Surgical

Pursuing One and Done Cancer Surgeries by Enabling True Surgeon - Pathologist Collaboration to Reduce the Reoperation Rate

Claim My Business
Min Investment
Denver, CO
Expected Close Date
June 24, 2024
Target Raise
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

Emet Surgical is aiming to improve cancer surgery outcomes by offering innovative tools for tumor marking, enabling better collaboration between surgeons and pathologists. Our goal is to enhance patient results while providing improved ROI for healthcare providers and insurers. Emet Surgical is a pre-revenue business currently in the development stage.

Key Deal Facts

We believe our TrueMargin™ tools can help revolutionize cancer surgeries, reducing re-operation rates with innovative Colored Marking Sutures and Clips.

With millions worldwide undergoing breast cancer surgeries yearly, Emet Surgical's technology addresses a pressing need for improved surgical outcomes, offering substantial market potential.*

Backed by patent claims filed for TrueMargin and TrueGastro and expanding our portfolio with applications for packaging and manufacturing processes, our goal is FDA clearance in Q2 2024.

Emet Surgical is a pre-revenue business currently in the development stage.
Amount Raised : $9,882
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Research Reports

No reports have been submitted

Become a Reporter